NSE: LUPIN | BSE: 500257

Mid-range Performer

Download real time

2261.20 11.40 (0.51%)

52W high on May 07, 2026

594.3K NSE+BSE Volume

NSE 03 Jun, 2026 3:31 PM (IST)

103,385.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

US FDA Approval

Lupin's ANDA Sodium Sulfate, Magnesium Sulfate, and Potassium Chloride tablets get US FDA approval See details

Lupin Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for LUPIN, BSE:500257 Lupin Ltd.

Search Inside the pdf :

Lupin Ltd.

14 May 2026

2261.20

0.51%

Outlook

Hold: Lupin Ltd.

Recommendation Target

Deven Choksey

The company’s near-term earnings outlook is expected to go through a transition phase rather than maintain strong growth momentum.

Lupin Ltd. is trading above its 200 day SMA of 2133.0

Lupin Ltd.

11 May 2026

2261.20

0.51%

Lupin (LPC IN) Q4FY26 Result Update Sustainability of US sales will be key ACCUMULATE

Accumulate: Lupin Ltd.

Recommendation Target

Prabhudas Lilladhar

Higher US revenues spur growth YoY: Revenues grew 33% YoY to INR 74bn, vs our estimate INR 69.4bn. Beat was on account of higher US revenues which stood at USD contribution from gTolvaptan, continued flu season and other launches. India formulation grew by 11.5% YoY. EMs increased sharply by 49%, while other developed markets increased by 7% YoY. API business showed recovery up 8% YoY....

Number of FII/FPI investors increased from 966 to 979 in Mar 2026 qtr.

Lupin Ltd.

10 May 2026

2261.20

0.51%

Lupin (BUY): On the verge of becoming a USD 1bn EBITDA company by FY29

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA/APAT surpassed our 4QFY26 estimates by 8.1%/18.5%/12.7% respectively; EBITDA Margin by 254 bps

Lupin Ltd. is trading above its 200 day SMA of 2133.0

Lupin Ltd.

10 May 2026

2261.20

0.51%

Broad-based growth drives earnings; strong finish in FY26

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) delivered another quarter of strong performance with a 7%/11%/10% beat on revenue/EBITDA/PAT for the quarter.

Lupin Ltd. has an average target of 2436.64 from 11 brokers.

Lupin Ltd.

16 Feb 2026

2261.20

0.51%

Dependency on US exclusivity rising

Hold: Lupin Ltd.

Target

ICICI Securities Limited

Beat in Q3FY26 vs our expectation was mainly driven by stellar performance in the US region, posting revenue of USD 350mn (up 46.8% YoY). Apart from a few seasonal products, sales in US were largely led by Tolvaptan, Mirabegron and Spiriva.

Lupin Ltd. is trading below its 30 day SMA of 2299.6

Lupin Ltd.

16 Feb 2026

2261.20

0.51%

Result Update:Lupin

Buy: Lupin Ltd.

Target

Axis Direct

We recommend a BUY rating with a target price of Rs 2,460/share.

Number of FII/FPI investors increased from 966 to 979 in Mar 2026 qtr.

Lupin Ltd.

15 Feb 2026

2261.20

0.51%

Lupin (BUY): Multiple growth levers for multiple years

Buy: Lupin Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /APAT reported 8.2%/13.1%/25% above our estimates. EBITDA Margin reported 130 bps above our estimates

Lupin Ltd. is trading below its 30 day SMA of 2299.6

Lupin Ltd.

14 Feb 2026

2261.20

0.51%

Strong execution drives margin to decade high

Neutral: Lupin Ltd.

Target

Motilal Oswal

Lupin (LPC) posted a better-than-expected financial performance in 3QFY26, with 6%/16%/22% beat on revenues/EBITDA/PAT. Robust traction in US and other developed markets helped LPC sustain profitable growth momentum in 3Q.